Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Israel | 23 | 2021 | 2751 | 1.03 | Why? |
| Mass Vaccination | 3 | 2021 | 1101 | 0.94 | Why? |
| Glycated Hemoglobin A | 3 | 2021 | 1316 | 0.82 | Why? |
| Gastroplasty | 1 | 2018 | 20 | 0.74 | Why? |
| Anthrax | 1 | 2018 | 35 | 0.71 | Why? |
| Hyperlipoproteinemias | 1 | 2017 | 7 | 0.71 | Why? |
| Epidemiologic Measurements | 1 | 2018 | 107 | 0.70 | Why? |
| Bioterrorism | 1 | 2018 | 105 | 0.69 | Why? |
| Patient Navigation | 1 | 2018 | 62 | 0.69 | Why? |
| Cholesterol, LDL | 2 | 2017 | 499 | 0.63 | Why? |
| Biological Science Disciplines | 1 | 2017 | 72 | 0.63 | Why? |
| Gastrectomy | 1 | 2018 | 225 | 0.62 | Why? |
| Gastric Bypass | 1 | 2018 | 152 | 0.60 | Why? |
| Osteoporotic Fractures | 1 | 2017 | 175 | 0.55 | Why? |
| Patient Participation | 2 | 2018 | 829 | 0.53 | Why? |
| Cell Phone | 1 | 2018 | 750 | 0.41 | Why? |
| Hip Fractures | 1 | 2017 | 667 | 0.37 | Why? |
| Noncommunicable Diseases | 1 | 2017 | 934 | 0.35 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.35 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.34 | Why? |
| Medication Adherence | 4 | 2018 | 1270 | 0.34 | Why? |
| Kaplan-Meier Estimate | 4 | 2021 | 4260 | 0.34 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.33 | Why? |
| Antidepressive Agents | 3 | 2017 | 509 | 0.33 | Why? |
| Obesity, Morbid | 1 | 2018 | 1340 | 0.32 | Why? |
| Diabetes Complications | 1 | 2018 | 2358 | 0.31 | Why? |
| Laparoscopy | 1 | 2018 | 1532 | 0.31 | Why? |
| Quality of Health Care | 1 | 2018 | 1948 | 0.31 | Why? |
| Cardiovascular Diseases | 3 | 2021 | 11497 | 0.30 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.30 | Why? |
| Myocarditis | 1 | 2021 | 2731 | 0.29 | Why? |
| Diabetes Mellitus, Type 2 | 3 | 2021 | 6166 | 0.26 | Why? |
| Algorithms | 2 | 2018 | 7346 | 0.25 | Why? |
| Primary Health Care | 2 | 2018 | 4839 | 0.24 | Why? |
| Urinary Tract Infections | 2 | 2019 | 534 | 0.24 | Why? |
| Delivery of Health Care | 3 | 2019 | 15909 | 0.23 | Why? |
| National Health Programs | 2 | 2019 | 807 | 0.22 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.21 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.21 | Why? |
| Insurance Claim Reporting | 1 | 2019 | 22 | 0.20 | Why? |
| Electronic Health Records | 3 | 2019 | 3492 | 0.20 | Why? |
| Hospitals | 2 | 2018 | 11793 | 0.19 | Why? |
| Bacillus anthracis | 1 | 2018 | 42 | 0.18 | Why? |
| Unsupervised Machine Learning | 1 | 2018 | 59 | 0.18 | Why? |
| 2-Naphthylamine | 1 | 2017 | 54 | 0.18 | Why? |
| Proportional Hazards Models | 4 | 2018 | 6543 | 0.17 | Why? |
| Diabetes Mellitus | 2 | 2017 | 8207 | 0.17 | Why? |
| Precision Medicine | 2 | 2018 | 1477 | 0.17 | Why? |
| Jews | 1 | 2019 | 117 | 0.17 | Why? |
| Fluoroquinolones | 1 | 2019 | 235 | 0.17 | Why? |
| Macrocyclic Compounds | 1 | 2017 | 78 | 0.17 | Why? |
| Genotype | 2 | 2021 | 4697 | 0.17 | Why? |
| Uracil | 1 | 2017 | 101 | 0.17 | Why? |
| Lactams, Macrocyclic | 1 | 2017 | 130 | 0.17 | Why? |
| Otitis Media | 1 | 2018 | 106 | 0.16 | Why? |
| Public Sector | 1 | 2019 | 204 | 0.16 | Why? |
| Anilides | 1 | 2017 | 105 | 0.16 | Why? |
| RNA, Messenger | 2 | 2021 | 5131 | 0.16 | Why? |
| Private Sector | 1 | 2019 | 262 | 0.16 | Why? |
| Social Class | 3 | 2021 | 1360 | 0.16 | Why? |
| Nonlinear Dynamics | 1 | 2017 | 177 | 0.15 | Why? |
| Arabs | 1 | 2019 | 298 | 0.15 | Why? |
| Lipoproteins, HDL | 1 | 2017 | 154 | 0.15 | Why? |
| Herpes Zoster | 1 | 2021 | 331 | 0.15 | Why? |
| Data Warehousing | 1 | 2017 | 116 | 0.15 | Why? |
| Calibration | 1 | 2017 | 307 | 0.15 | Why? |
| Risk Assessment | 2 | 2017 | 25439 | 0.15 | Why? |
| Benzodiazepines | 1 | 2017 | 163 | 0.15 | Why? |
| Security Measures | 1 | 2018 | 211 | 0.15 | Why? |
| Valine | 1 | 2017 | 359 | 0.15 | Why? |
| Lymphadenopathy | 1 | 2021 | 444 | 0.15 | Why? |
| Escherichia coli Infections | 1 | 2019 | 348 | 0.14 | Why? |
| HLA Antigens | 1 | 2021 | 830 | 0.14 | Why? |
| Proline | 1 | 2017 | 345 | 0.14 | Why? |
| Middle Aged | 24 | 2021 | 270681 | 0.14 | Why? |
| Syncope | 1 | 2018 | 238 | 0.14 | Why? |
| Triglycerides | 1 | 2017 | 478 | 0.14 | Why? |
| Cyclopropanes | 1 | 2017 | 332 | 0.14 | Why? |
| Aged, 80 and over | 13 | 2021 | 88759 | 0.14 | Why? |
| Male | 29 | 2021 | 367725 | 0.14 | Why? |
| Female | 29 | 2021 | 380317 | 0.14 | Why? |
| Cholesterol, HDL | 1 | 2017 | 439 | 0.14 | Why? |
| Risk Factors | 8 | 2021 | 71621 | 0.14 | Why? |
| Patient Simulation | 1 | 2018 | 338 | 0.14 | Why? |
| Adalimumab | 1 | 2018 | 389 | 0.13 | Why? |
| Humans | 41 | 2021 | 930598 | 0.13 | Why? |
| Goals | 1 | 2017 | 335 | 0.13 | Why? |
| Pharyngitis | 1 | 2018 | 687 | 0.13 | Why? |
| Aged | 19 | 2021 | 215776 | 0.13 | Why? |
| Bone Density | 1 | 2017 | 335 | 0.13 | Why? |
| Data Accuracy | 1 | 2019 | 715 | 0.13 | Why? |
| Carbamates | 1 | 2017 | 485 | 0.13 | Why? |
| Retrospective Studies | 14 | 2021 | 105322 | 0.13 | Why? |
| Drug Utilization | 1 | 2018 | 619 | 0.12 | Why? |
| Dyslipidemias | 1 | 2019 | 791 | 0.12 | Why? |
| Self-Management | 1 | 2018 | 546 | 0.12 | Why? |
| Pediatric Obesity | 1 | 2017 | 492 | 0.12 | Why? |
| Glomerular Filtration Rate | 1 | 2018 | 1262 | 0.12 | Why? |
| Referral and Consultation | 2 | 2019 | 4816 | 0.12 | Why? |
| Psychosocial Support Systems | 1 | 2018 | 710 | 0.12 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.12 | Why? |
| Weight Loss | 1 | 2018 | 826 | 0.12 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.11 | Why? |
| Appendicitis | 1 | 2021 | 946 | 0.11 | Why? |
| Incidence | 5 | 2021 | 25622 | 0.11 | Why? |
| Escherichia coli | 1 | 2019 | 1547 | 0.11 | Why? |
| Adult | 20 | 2021 | 244371 | 0.11 | Why? |
| Sinusitis | 1 | 2018 | 649 | 0.10 | Why? |
| Age Factors | 4 | 2021 | 21039 | 0.10 | Why? |
| Cluster Analysis | 1 | 2018 | 3001 | 0.10 | Why? |
| Young Adult | 12 | 2021 | 93724 | 0.10 | Why? |
| Primary Prevention | 1 | 2017 | 778 | 0.10 | Why? |
| Depressive Disorder | 2 | 2017 | 1236 | 0.10 | Why? |
| Perception | 2 | 2019 | 2827 | 0.10 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.10 | Why? |
| Drug Resistance, Bacterial | 1 | 2019 | 1414 | 0.10 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.09 | Why? |
| Risk | 1 | 2021 | 5288 | 0.09 | Why? |
| Immunogenicity, Vaccine | 2 | 2021 | 4624 | 0.09 | Why? |
| Drug Prescriptions | 1 | 2017 | 1062 | 0.09 | Why? |
| Sulfonamides | 1 | 2017 | 1294 | 0.09 | Why? |
| Patient Satisfaction | 2 | 2019 | 2517 | 0.09 | Why? |
| Hypoglycemic Agents | 2 | 2021 | 2165 | 0.09 | Why? |
| Patient Compliance | 1 | 2017 | 1468 | 0.08 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Cohort Studies | 9 | 2021 | 36005 | 0.08 | Why? |
| Cause of Death | 2 | 2019 | 4823 | 0.08 | Why? |
| Community-Acquired Infections | 1 | 2019 | 2328 | 0.08 | Why? |
| Depressive Disorder, Major | 1 | 2015 | 852 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.07 | Why? |
| Treatment Outcome | 4 | 2021 | 51732 | 0.07 | Why? |
| Rubella virus | 1 | 2004 | 46 | 0.07 | Why? |
| Parkinson Disease | 1 | 2017 | 1414 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2018 | 1996 | 0.07 | Why? |
| Atrial Fibrillation | 1 | 2018 | 2320 | 0.06 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.06 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.06 | Why? |
| Models, Statistical | 1 | 2020 | 5312 | 0.06 | Why? |
| Ritonavir | 1 | 2017 | 4212 | 0.06 | Why? |
| Influenza Vaccines | 1 | 2018 | 2941 | 0.06 | Why? |
| Healthcare Disparities | 1 | 2019 | 3893 | 0.05 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.05 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.05 | Why? |
| Histocompatibility Testing | 1 | 2021 | 219 | 0.05 | Why? |
| Sex Factors | 4 | 2019 | 11014 | 0.05 | Why? |
| Surveys and Questionnaires | 4 | 2020 | 43792 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2019 | 5002 | 0.05 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.05 | Why? |
| Anti-Bacterial Agents | 2 | 2019 | 10083 | 0.05 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.05 | Why? |
| SARS Virus | 1 | 2003 | 13021 | 0.05 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2003 | 12361 | 0.05 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.05 | Why? |
| Bacteriuria | 1 | 2019 | 31 | 0.05 | Why? |
| Pulmonary Embolism | 1 | 2018 | 4775 | 0.05 | Why? |
| Age Distribution | 2 | 2018 | 3567 | 0.04 | Why? |
| Genetic Association Studies | 1 | 2021 | 559 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2018 | 6817 | 0.04 | Why? |
| Haplotypes | 1 | 2021 | 853 | 0.04 | Why? |
| Stroke | 2 | 2018 | 8839 | 0.04 | Why? |
| Private Practice | 1 | 2019 | 203 | 0.04 | Why? |
| Absenteeism | 1 | 2018 | 287 | 0.04 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.04 | Why? |
| Alleles | 1 | 2021 | 1557 | 0.04 | Why? |
| Inappropriate Prescribing | 1 | 2018 | 284 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2017 | 1008 | 0.03 | Why? |
| Child, Preschool | 4 | 2021 | 36283 | 0.03 | Why? |
| Virulence | 1 | 2021 | 2172 | 0.03 | Why? |
| Influenza, Human | 1 | 2018 | 10779 | 0.03 | Why? |
| Logistic Models | 2 | 2019 | 9089 | 0.03 | Why? |
| Emigration and Immigration | 1 | 2019 | 501 | 0.03 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Vaccination | 1 | 2018 | 19050 | 0.03 | Why? |
| Child | 5 | 2021 | 70012 | 0.03 | Why? |
| Lipids | 1 | 2019 | 1079 | 0.03 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.03 | Why? |
| Health Services | 1 | 2018 | 765 | 0.03 | Why? |
| Respiratory Syncytial Virus, Human | 1 | 2018 | 846 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Sex Distribution | 1 | 2018 | 2083 | 0.03 | Why? |
| Cross-Sectional Studies | 4 | 2019 | 53120 | 0.03 | Why? |
| Patient Readmission | 1 | 2019 | 1543 | 0.02 | Why? |
| Intracranial Hemorrhages | 1 | 2018 | 1170 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.02 | Why? |
| Linear Models | 1 | 2015 | 1914 | 0.02 | Why? |
| Interviews as Topic | 1 | 2017 | 1952 | 0.02 | Why? |
| Health Personnel | 1 | 2018 | 29646 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Physician-Patient Relations | 1 | 2017 | 1266 | 0.02 | Why? |
| Infant, Newborn | 2 | 2021 | 23105 | 0.02 | Why? |
| Blood Glucose | 1 | 2021 | 3642 | 0.02 | Why? |
| Health Status | 1 | 2020 | 3259 | 0.02 | Why? |
| Telemedicine | 1 | 2018 | 25032 | 0.02 | Why? |
| Emigrants and Immigrants | 1 | 2015 | 888 | 0.02 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Infant | 2 | 2021 | 30274 | 0.02 | Why? |
| Qualitative Research | 1 | 2017 | 4337 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Pediatrics | 1 | 2019 | 2969 | 0.02 | Why? |
| Rubella | 1 | 2004 | 127 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2018 | 3023 | 0.02 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.02 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.02 | Why? |
| Socioeconomic Factors | 1 | 2019 | 8495 | 0.01 | Why? |
| Length of Stay | 1 | 2019 | 11042 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Physicians | 1 | 2019 | 4214 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2003 | 15421 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Public Health | 1 | 2003 | 16359 | 0.01 | Why? |
| Anticoagulants | 1 | 2018 | 9563 | 0.01 | Why? |
| Hospital Mortality | 1 | 2019 | 22087 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2004 | 51949 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Seroepidemiologic Studies | 1 | 2004 | 10017 | 0.01 | Why? |
| Prospective Studies | 1 | 2004 | 43301 | 0.00 | Why? |
Balicer's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(224)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(167)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_